Acacia Parks, PhD, MBA, Advisor to Lindus Health, discusses the journey to commercialisation for digital therapeutics and how best to engage the FDA in this process. While there is no “one size fits all” approach to the development of any class of treatments, this is especially true for digital therapeutics (DTx). Being so new to […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
